Soma (R) 350mg tablets with Carisoprodol

Soma ® 350mg tablets
Active ingredient: Carisoprodol

How does the component?
Carisoprodol relaxes muscles and relieves pain and discomfort by strains, sprains, spasms or other muscle injuries. Muscle relaxers are for specific muscle injury and should not be used to treat general body aches.

Applications
Muscle relaxation

Warnings!
SOMA has a sedative effect and may impair the mental and / or physical abilities, is therefore of potentially hazardous tasks such as driving a motor vehicle or machinery discouraged.

The sedative effects of SOMA and other CNS depressants (eg alcohol, benzodiazepines, opiates, tricyclic antidepressants) may be mutually reinforcing. Therefore, special care should be exercised in patients concurrently taking more than one of these CNS depressants.


When the drug is not suitable for you (contraindications)?
Carisoprodol is contraindicated in patients with a history of acute porphyria or a hypersensitivity reaction to a carbamate such as meprobamate.

Pregnancy and lactation
Carisoprodol is excreted through breast milk. Nursing mothers should refrain from taking carisoprodol preparations.

Side effects
Listed are the major known side effects. They can occur, but need not, as each person responds differently to medications.

Sometimes people have allergic reactions to medications. If you have any signs of an allergic reaction, stop and call your doctor or pharmacist.

Stomach upsets

Heartburn

Headache

Dizziness

Dizziness

Allergic reactions (rare)

(Symptoms: rash, itching, swelling, dizziness and respiratory problems, acute urticaria (hives), fixed drug eruption)


Interactions
To the interaction of carisoprodol with other agents is limited experience.

CNS depressants

The calming effects of SOMA and other CNS depressants (eg alcohol, benzodiazepines, opiates, tricyclic antidepressants) may be enhanced. Therefore, caution is advised in patients taking more than one of these CNS depressants simultaneously. Concomitant use of SOMA and meprobamate, a metabolite of SOMA is not recommended.

CYP2C19 inhibitors and inducers

Carisoprodol is metabolized in the liver by CYP2C19 to meprobamate. The concomitant administration of CYP2C19 inhibitors such as omeprazole or fluvoxamine, with SOMA could result in an increased exposure of carisoprodol and meprobamate lower exposure. The concomitant administration of CYP2C19 inducers such as rifampicin or St John's wort with SOMA could result in decreased exposure of carisoprodol and increased exposure of meprobamate. Low dose aspirin also showed an effect on CYP2C19. The full pharmacological impact of these possible changes of requirements in terms of either efficacy or safety of SOMA is unknown.

This text makes no claim to completeness. It will only be clinically significant information. The description is neutral and based on the Federal Institute for Drugs and Medical Devices (BfArM) approved SPC. The information does not endorse or promote the drug They also do not replace the advice of a doctor or pharmacist.